Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinergic Receptors: Nicotinic01:15

Cholinergic Receptors: Nicotinic

2.1K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
2.1K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

1.4K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.4K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

1.5K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.5K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

784
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
784
Allosteric Regulation01:08

Allosteric Regulation

57.4K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.4K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

828
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
828

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bio-Based Self-Curing Phthalonitrile Resins Derived from Cinnamaldehyde.

Polymer science & technology (Washington, D.C.)·2026
Same author

Dual-Ligand Targeted Nanoparticles Enhance In Vitro Delivery and Efficacy of Investigational Drug Candidate GAT211.

ACS applied bio materials·2025
Same author

Optimization of Quinazolines for Inhibition of <i>Trypanosoma brucei</i> Proliferation.

ACS medicinal chemistry letters·2025
Same author

Crystal structure and Hirshfeld surface analysis of 5-(3-nitro-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-tetra-zole.

Acta crystallographica. Section E, Crystallographic communications·2025
Same author

Stereoisomers of Chiral Methyl-Substituted Symmetric and Asymmetric Aryl Piperazinium Compounds Exhibit Distinct Selectivity for α9 and α7 Nicotinic Acetylcholine Receptors.

ACS chemical neuroscience·2025
Same author

A mechanistic understanding of the effect of <i>Staphylococcus aureus</i> VraS histidine kinase single-point mutation on antibiotic resistance.

Microbiology spectrum·2025

Related Experiment Video

Updated: May 23, 2025

Local Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices
10:04

Local Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices

Published on: October 29, 2012

19.2K

Enantiospecific Positive Allosteric Modulation of α4β2 Nicotinic Receptor Subtypes.

Josue Gaona1, Pradip K Gadekar2, Khaldoun S Abdelwahed1

  • 1Department of Pharmaceutical Sciences and Health Outcomes, The University of Texas at Tyler, Tyler, Texas 75799, United States.

ACS Chemical Neuroscience
|April 29, 2025
PubMed
Summary

Researchers developed GAT2802, a selective positive allosteric modulator (PAM) for alpha4beta2 nicotinic acetylcholine receptors (nAChRs). This compound shows promise for treating nicotine addiction and cognitive disorders by enhancing nAChR function.

Keywords:
chiral separation and X-ray crystallographycognitive disorderscomputational dockingnicotine addictionnicotinic acetylcholine receptorspositive allosteric modulatorstwo-electrode voltage clamp (TEVC)α4β2 nAChRs

More Related Videos

Utilizing pHluorin-tagged Receptors to Monitor Subcellular Localization and Trafficking
09:59

Utilizing pHluorin-tagged Receptors to Monitor Subcellular Localization and Trafficking

Published on: March 16, 2017

8.8K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K

Related Experiment Videos

Last Updated: May 23, 2025

Local Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices
10:04

Local Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices

Published on: October 29, 2012

19.2K
Utilizing pHluorin-tagged Receptors to Monitor Subcellular Localization and Trafficking
09:59

Utilizing pHluorin-tagged Receptors to Monitor Subcellular Localization and Trafficking

Published on: March 16, 2017

8.8K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Nicotinic acetylcholine receptors (nAChRs), particularly alpha4beta2 subtypes, are crucial for cognitive functions and reward pathways.
  • Dysregulation of alpha4beta2 nAChRs is implicated in nicotine addiction and cognitive impairments, making them key therapeutic targets.

Purpose of the Study:

  • To synthesize, resolve, and pharmacologically characterize GAT2800, a novel positive allosteric modulator (PAM) of alpha4beta2 nAChRs.
  • To evaluate the enantiomers of GAT2800 for their activity, selectivity, and potential therapeutic applications in neurological disorders.

Main Methods:

  • Synthesis and stereochemical resolution of GAT2800 to isolate its S- and R-enantiomers (GAT2801 and GAT2802).
  • Pharmacological evaluation using two-electrode voltage-clamp recordings in Xenopus oocytes expressing different nAChR subtypes.
  • X-ray crystallography for configuration confirmation, computational docking, and mutational analyses to determine binding sites and selectivity determinants.
  • In vitro safety assessments in HEK cells and in vivo developmental toxicity studies in zebrafish larvae.

Main Results:

  • GAT2802, the R-enantiomer, was identified as a potent PAM of both high-sensitivity (HS) and low-sensitivity (LS) alpha4beta2 nAChR isoforms, with EC50 values around 0.8-1 μM.
  • GAT2802 demonstrated significant potentiation of acetylcholine-evoked currents at HS alpha4beta2 nAChRs with minimal activity at alpha3-containing nAChRs.
  • Mutational analysis identified alpha4Cys233 as critical for GAT2802's selectivity towards alpha4-containing nAChRs.
  • GAT2802 exhibited negligible cellular toxicity and no significant developmental effects in zebrafish at concentrations up to 100 μM.

Conclusions:

  • GAT2802 is a highly selective and potent positive allosteric modulator of alpha4beta2 nAChRs.
  • Its favorable safety profile and specific mechanism of action position it as a promising lead compound for developing novel therapeutics for nicotine addiction and cognitive disorders.
  • Further research into GAT2802 could pave the way for new treatments targeting nAChR-related neurological conditions.